Insertable or implantable cardiac monitors (ICMs) continuously monitor the heart rhythm and record irregularities over 3 years, enabling the diagnosis of infrequent rhythm abnormalities associated with syncope and stroke. The enhanced recognition capabilities of recent ICM models are able to accurately detect atrial fibrillation (AF) and have led to new applications of ICMs for the detection and monitoring of AF.
Methods and results
Based on a systematic literature search, two indications were identified for ICMs for which considerable evidence, including randomized studies, exists: diagnosing the underlying cardiac cause of unexplained recurrent syncope and detecting AF in patients after cryptogenic stroke (CS). Three randomized controlled trials (RCTs) were identified that compared the effectiveness of ICMs in diagnosing patients with unexplained syncope (n = 556) to standard of care. A meta-analysis was conducted in order to generate an overall effect size and confidence interval of the diagnostic yield of ICMs versus conventional monitoring. In the indication CS, one RCT and five observational studies were included in order to assess the performance of ICMs in diagnosing patients with AF (n = 1129). Based on these studies, there is strong evidence that ICMs provide a higher diagnostic yield for detecting arrhythmias in patients with unexplained syncope and for detection of AF in patients after CS compared to conventional monitoring.
Conclusions
Prolonged monitoring with ICMs is an effective tool for diagnosing the underlying cardiac cause of unexplained syncope and for detecting AF in patients with CS. In all RCTs, ICMs have a superior diagnostic yield compared to conventional monitoring.
Task Force for the Diagnosis Management of SyncopeEuropean Society of CardiologyEuropean Heart Rhythm Association, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J2009; 30: 2631–2671.
2.
BrignoleMVardasPHoffmanE. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace2009; 11: 671–687.
3.
PurerfellnerHPokushalovESarkarS. P-wave evidence as a method for improving algorithm to detect atrial fibrillation in insertable cardiac monitors. Heart Rhythm2014; 11: 1575–1583.
4.
HindricksGPokushalovEUrbanL. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol2010; 3: 141–217.
5.
EitelCHusserDHindricksG. Performance of an implantable automatic atrial fibrillation detection device: impact of software adjustments and relevance of manual episode analysis. Europace2011; 13: 480–485.
6.
SoteriadesESEvansJCLarsonMG. Incidence and prognosis of syncope. N Engl J Med2002; 347: 878–885.
7.
HuikuriHVCastellanosAMyerburgRJ. Sudden death due to cardiac arrhythmias. N Engl J Med2001; 345: 1473–1482.
8.
SunBC. Quality-of-life, health service use, and costs associated with syncope. Prog Cardiovasc Dis2013; 55: 370–375.
9.
SuttonRBendittDG. Epidemiology and economic impact of cardiac syncope in western countries. Future Cardiol2012; 8: 467–472.
10.
ShiyovichAMunchakIZelingherJ. Admission for syncope: evaluation, cost and prognosis according to etiology. Isr Med Assoc J2008; 10: 104–108.
11.
BartolettiAFabianiPBagnoliL. Physical injuries caused by a transient loss of consciousness: main clinical characteristics of patients and diagnostic contribution of carotid sinus massage. Eur Heart J2008; 29: 618–624.
12.
LinzerMPontinenMGoldDT. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol1991; 44: 1037–1043.
13.
van DijkNSprangersMAColmanN. Clinical factors associated with quality of life in patients with transient loss of consciousness. J Cardiovasc Electrophysiol2006; 17: 998–1003.
14.
VitaleEUngarAMaggiR. Discrepancy between clinical practice and standardized indications for an implantable loop recorder in patients with unexplained syncope. Europace2010; 12: 1475–1479.
15.
SciaraffiaEChenJHociniM. Use of event recorders and loop recorders in clinical practice: results of the European Heart Rhythm Association Survey. Europace2014; 16: 1384–1386.
16.
National Clinical Guideline Centre for Acute and Chronic Conditions. Transient Loss of Consciousness (‘Blackouts’) Management in Adults and Young People. NICE Clinical Guidelines, No. 109. London, 2010.
17.
The Task Force on Cardiac Pacing and Resynchronization Therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J2013; 34: 2281–2329.
18.
GregoratosGAbramsJEpsteinAE. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol2002; 13: 1183–1199.
19.
BrignoleMSuttonRMenozziC. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J2006; 27: 1085–1092.
20.
BrignoleMMenozziCMoyaA. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation2012; 125: 2566–2571.
Luengo-FernandezRYiinGSGrayAM. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke2013; 8: 308–314.
23.
GuerciniFAcciarresiMAgnelliG. Cryptogenic stroke: time to determine aetiology. J Thromb Haemostat2008; 6: 549–554.
24.
MohanKMWolfeCDRuddAG. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011. 42: 1489–1494.
25.
WolfPADawberTRThomasHEJr.. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology1978; 28: 973–977.
26.
WangTJMassaroJMLevyD. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA2003; 290: 1049–1056.
27.
SposatoLACiprianoLESaposnikG. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol2015; 14: 377–387.
28.
JauchECSaverJLAdamsHPJr.. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013; 44: 870–947.
29.
European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis2008; 25: 457–507.
30.
VermaACairnsJAMitchellLB. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol2014; 30: 1114–1130.
31.
Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 1330-1338.
32.
AfzalMRGundaSWaheedS. Role of outpatient cardiac rhythm monitoring in cryptogenic stroke: a systematic review and meta-analysis. Pacing Clin Electrophysiol2015; 38: 1236–1245.
33.
OlsenFJBiering-SorensenTKriegerDW. An update on insertable cardiac monitors: examining the latest clinical evidence and technology for arrhythmia management. Future Cardiol2015; 11: 333–346.
34.
DussaultCToegHNathanM. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. Circ Arrhythm Electrophysiol2015; 8: 263–269.
35.
DienerHCEikelboomJConnollySJ. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol2012; 11: 225–231.
36.
Kanters TA, Wolff C, Boyson D, et al. Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. Europace 2015 [Epub ahead of print].
37.
Drak-HernandezYToquero-RamosJFernandezJM. Effectiveness and safety of remote monitoring of patients with an implantable loop recorder. Rev Esp Cardiol (Engl Ed)2013; 66: 943–948.
38.
GlanvilleJMLefebvreCMilesJN. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc2006; 94: 130–136.
39.
FurlanADIrvinEBombardierC. Limited search strategies were effective in finding relevant nonrandomized studies. J Clin Epidemiol2006; 59: 1303–1311.
40.
Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland. Critical Appraisal: Notes and checklists. Edinburgh, UK. http://www.sign.ac.uk/methodology/checklists.html (accessed 07 September 2015).
41.
Viechtbauer W. Conducting meta-analyses in R with the Metafor package. J Stat Softw 2010; 36.
42.
DuvalSTweedieR. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000; 56: 455–463.
43.
HigginsJPAltmanDGGotzschePC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928–d5928.
44.
FarwellDJFreemantleNSulkeAN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J2004; 25: 1257–1263.
45.
FarwellDJFreemantleNSulkeN. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J2006; 27: 351–356.
46.
Da CostaADefayePRomeyer-BouchardC. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative workup: a randomized multicentre prospective study. Arch Cardiovasc Dis2013; 106: 146–154.
47.
KrahnADKleinGJYeeR. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation2001; 104: 46–51.
48.
KrahnADKleinGJYeeR. Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial. J Am Coll Cardiol2003; 42: 495–501.
49.
CotterPEMartinPJRingL. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology2013; 80: 1546–1550.
50.
DionFSaudeauDBonnaudI. Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study. J Interv Card Electrophysiol2010; 28: 101–107.
51.
EtgenTHochreiterMMundelM. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. Stroke2013; 44: 2007–2009.
52.
RitterMAKochhauserSDuningT. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke2013; 44: 1449–1452.
53.
ChristensenLMKriegerDWHøjbergS. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. Eur J Neurol2014; 21: 884–889.
54.
Rojo-MartinezESandin-FuentesMCalleja-SanzAI. [High performance of an implantable Holter monitor in the detection of concealed paroxysmal atrial fibrillation in patients with cryptogenic stroke and a suspected embolic mechanism]. Rev Neurol2013; 57: 251–257.
55.
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
56.
SannaTDienerH-CPassmanRS. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med2014; 370: 2478–2486.
57.
KrahnADKleinGJYeeR. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation1999; 99: 406–410.
58.
EdvardssonNWolffCTsintzosS. Costs of unstructured investigation of unexplained syncope: insights from a micro-costing analysis of the observational PICTURE registry. Europace2015; 17: 1141–1148.
59.
KachaliaABergAFagerlinA. Overuse of testing in preoperative evaluation and syncope: a survey of hospitalists. Ann Intern Med2015; 162: 100–108.
60.
PodoleanuCDaCostaADefayeP. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch Cardiovasc Dis2014; 107: 546–552.
61.
ProvidenciaRCandeiasRMoraisC. Financial impact of adopting implantable loop recorder diagnostic for unexplained syncope compared with conventional diagnostic pathway in Portugal. BMC Cardiovasc Disord2014; 14: 63–63.
62.
DavisSWestbyMPitcherD. Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained. Europace2012; 14: 402–409.
63.
KishoreAVailAMajidA. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke2014; 45: 520–526.
64.
Choe WC, Passman RS, Brachmann J, et al. A Comparison of Atrial Fibrillation Monitoring Strategies After Cryptogenic Stroke (from the Cryptogenic Stroke and Underlying AF Trial). Am J Cardiol 2015.
65.
Luengo-FernandezRGrayAMBullL. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology2013; 81: 1588–1595.
66.
Diamantopoulos A, Sawyer L, Lip GYH, et al. Use of an insertable cardiac monitor to detect atrial fibrillation is cost effective in patients with cryptogenic stroke. In: International Stroke Conference, Nashville, TN, USA, 11 February 2015–13 February 2015.
67.
Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20(3): 241–248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
